Anthony Gordon (scientist)

Last updated
Anthony Christopher Gordon

Anthony Gordon.jpg
NationalityBritish
Alma materSt Bartholomew's Hospital Medical School, University of London
Scientific career
Fields Critical Care Sepsis
InstitutionsImperial College London
Thesis Genetic polymorphisms of the innate immune system: influence on susceptibility and outcome in severe sepsis and septic shock
Doctoral advisor Charles Hinds
Website www.imperial.ac.uk/people/anthony.gordon

Anthony Gordon FRCA FFICM FMedSci is a British clinician scientist and the Chair of Anaesthesia & Critical Care at Imperial College London and works as an intensive care consultant at Imperial College Healthcare NHS Trust. [1]

Contents

Early life and education

Educated at Kings College School, Wimbledon, [2] he studied medicine at St Bartholomew's Hospital Medical School, University of London, and was awarded a BSc in Anatomy with Basic Medical Sciences in 1990 and MBBS in 1993. He undertook his doctoral studies with Charles Hinds and was awarded an MD for his thesis exploring genetic polymorphisms in sepsis [3]

Career and research

He undertook his postgraduate medical training in London with an additional year at Royal North Shore Hospital in Sydney, Australia [4] He was awarded the Intensive Care Society visiting fellowship in 2005 and spent two years in Vancouver at St Paul's Hospital, University of British Columbia [5] and also worked as the director of medical development of a university spin-out company (Sirius Genomics Inc) developing pharmacogenetic tests for use in the ICU. [6]

As an NIHR Research Professor (2016-2022) [7] he leads a multi-disciplinary team investigating the use of ‘omic techniques [8] and artificial intelligence (AI) [9] to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies. He was the Chief Investigator of the VANISH clinical trial evaluating early vasopressin use (in combination with hydrocortisone) [10] and the LeoPARDS trial evaluating levosimendan, [11] both in septic shock.

He is the UK Chief Investigator for the REMAP-CAP clinical trial, [12] which was the first trial to demonstrate that the immune modulating drugs, tocilizumab and sarilumab, saved lives from severe COVID-19. [13] The Prime Minister announced this result from 10 Downing Street [14] and Gordon is the first author of the published paper. [15] This adaptive platform trial has reported on more than a dozen other interventions for severe COVID-19, including hydrocortisone, convalescent plasma, anti-virals, anti-platelet drugs, [16] therapeutic heparin, [17] [18] ACE inhibitors and Angiotensin Receptor Blockers (ARBs), [19] high-dose vitamin C [20] and simvastatin. [21] The trial has now been selected by the NIHR as the national platform trial to find the most effective treatments for people hospitalised with severe flu. [22]

In March 2024 he was appointed as Programme Director of the National Research Collaboration Programme (NRCP). [23] The NRCP is an NIHR / NHS England partnership that commissions high quality evidence for treatments where research can present particular challenges and might otherwise not progress.

Honours

His contributions to clinical science have been recognised in appointment as a Fellow of the Academy of Medical Sciences (2022), [24] an Honorary Member of the Intensive Care Society [25] and NIHR Senior Investigator (2023) [26]

Related Research Articles

<span class="mw-page-title-main">Sepsis</span> Life-threatening organ dysfunction triggered by infection

Sepsis is a potentially life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs.

<span class="mw-page-title-main">Acute respiratory distress syndrome</span> Human disease

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath (dyspnea), rapid breathing (tachypnea), and bluish skin coloration (cyanosis). For those who survive, a decreased quality of life is common.

Hyperchloremia is an electrolyte disturbance in which there is an elevated level of chloride ions in the blood. The normal serum range for chloride is 96 to 106 mEq/L, therefore chloride levels at or above 110 mEq/L usually indicate kidney dysfunction as it is a regulator of chloride concentration. As of now there are no specific symptoms of hyperchloremia; however, it can be influenced by multiple abnormalities that cause a loss of electrolyte-free fluid, loss of hypotonic fluid, or increased administration of sodium chloride. These abnormalities are caused by diarrhea, vomiting, increased sodium chloride intake, renal dysfunction, diuretic use, and diabetes. Hyperchloremia should not be mistaken for hyperchloremic metabolic acidosis as hyperchloremic metabolic acidosis is characterized by two major changes: a decrease in blood pH and bicarbonate levels, as well as an increase in blood chloride levels. Instead those with hyperchloremic metabolic acidosis are usually predisposed to hyperchloremia.

Stress hyperglycemia is a medical term referring to transient elevation of the blood glucose due to the stress of illness. It usually resolves spontaneously, but must be distinguished from various forms of diabetes mellitus.

<span class="mw-page-title-main">Hemofiltration</span>

Hemofiltration, also haemofiltration, is a renal replacement therapy which is used in the intensive care setting. It is usually used to treat acute kidney injury (AKI), but may be of benefit in multiple organ dysfunction syndrome or sepsis. During hemofiltration, a patient's blood is passed through a set of tubing via a machine to a semipermeable membrane where waste products and water are removed by convection. Replacement fluid is added and the blood is returned to the patient.

<span class="mw-page-title-main">SOFA score</span> Medical assessment

The sequential organ failure assessment score, previously known as the sepsis-related organ failure assessment score, is used to track a person's status during the stay in an intensive care unit (ICU) to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.

<span class="mw-page-title-main">Dalteparin sodium</span> Pharmaceutical drug

Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.

David Lawrence Sackett was an American-Canadian physician and a pioneer in evidence-based medicine. He is known as one of the fathers of Evidence-Based Medicine. He founded the first department of clinical epidemiology in Canada at McMaster University, and the Oxford Centre for Evidence-Based Medicine. He is well known for his textbooks Clinical Epidemiology and Evidence-Based Medicine.

<span class="mw-page-title-main">Hydroxyethyl starch</span> Pharmaceutical drug

Hydroxyethyl starch (HES/HAES), sold under the brand name Voluven among others, is a nonionic starch derivative, used as a volume expander in intravenous therapy. The use of HES on critically ill patients is associated with an increased risk of death and kidney problems.

Early goal-directed therapy was introduced by Emanuel P. Rivers in The New England Journal of Medicine in 2001 and is a technique used in critical care medicine involving intensive monitoring and aggressive management of perioperative hemodynamics in patients with a high risk of morbidity and mortality. In cardiac surgery, goal-directed therapy has proved effective when commenced after surgery. The combination of GDT and Point-of-Care Testing has demonstrated a marked decrease in mortality for patients undergoing congenital heart surgery. Furthermore, a reduction in morbidity and mortality has been associated with GDT techniques when used in conjunction with an electronic medical record.

The National Institute for Health and Care Research (NIHR) is the British government’s major funder of clinical, public health, social care and translational research. With a budget of over £1.2 billion in 2020–21, its mission is to "improve the health and wealth of the nation through research". The NIHR was established in 2006 under the government's Best Research for Best Health strategy, and is funded by the Department of Health and Social Care. As a research funder and research partner of the NHS, public health and social care, the NIHR complements the work of the Medical Research Council. NIHR focuses on translational research, clinical research and applied health and social care research.

Paul Ellis Marik is an American medical doctor and former professor of medicine who until his resignation in January 2022 served as chair of the Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School in Norfolk, Virginia, and was also a critical care doctor at Sentara Norfolk General Hospital. His research interests include sepsis and tissue oxygenation. In August 2023 the American Board of Internal Medicine informed Marik his certification was to be revoked for spreading misinformation.

Vasodilatory shock, vasogenic shock, or vasoplegic shock is a medical emergency belonging to shock along with cardiogenic shock, septic shock, allergen-induced shock and hypovolemic shock. When the blood vessels suddenly relax, it results in vasodilation. In vasodilatory shock, the blood vessels are too relaxed leading to extreme vasodilation and blood pressure drops and blood flow becomes very low. Without enough blood pressure, blood and oxygen will not be pushed to reach the body's organs. If vasodilatory shock lasts more than a few minutes, the lack of oxygen starts to damage the body's organs. Vasodilatory shock like other types of shock should be treated quickly, otherwise it can cause permanent organ damage or death as a result of multiple organ dysfunction.

<span class="mw-page-title-main">Intravenous ascorbic acid</span> Nonmedical procedure

Intravenous Ascorbic Acid, is a process that delivers soluble ascorbic acid directly into the bloodstream. It is not approved for use to treat any medical condition.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. Some people may experience persistent symptoms or disability after recovery from the infection, known as long COVID, but there is still limited information on the best management and rehabilitation for this condition.

<span class="mw-page-title-main">RECOVERY Trial</span> Test of existing medicines on COVID-19

The Randomised Evaluation of COVID-19 Therapy is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. The trial was later expanded to Indonesia, Nepal and Vietnam. The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma.

<span class="mw-page-title-main">Justin Stebbing</span>

Justin Stebbing is Editor-in-Chief of Nature’s cancer journal Oncogene, a visiting Professor of Cancer Medicine and Oncology at Imperial College, London and a Professor of Biomedical Sciences at ARU, Cambridge. He works at the Phoenix Hospital Group in London to provide medical services to patients for the management of cancer, in person and remotely. He specialises in a range of solid malignancies including difficult cases with few conventional options and has published over 700 papers, the majority regarding new therapeutic and translational approaches including use of immunotherapies in clinical trials, many in the world's best journals.

Onyema Eberechukwu Ogbuagu is an American-born infectious diseases physician, educator, researcher, and clinical trial investigator, who was raised and educated in Nigeria. He is an associate professor at Yale School of Medicine in New Haven, CT and is the director of the Yale AIDS Program clinical trials unit. His research contributions have focused on HIV/AIDS prevention and COVID-19 vaccination and treatment clinical trials. He switched his focus at the beginning of the 2019 COVID pandemic and participated as a principal investigator (PI) on the Pfizer-BioNtech COVID-19 vaccine trials and the Remdesivir SIMPLE trial in 2020 and 2021. In pursuit of his global health component of his career, Ogbuagu also supports postgraduate physician medical education programs in low and middle income countries in sub-Saharan Africa in Rwanda (2013–2018) and Liberia as well as HIV treatment programs in Liberia.

The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is an international research initiative based in Oxford, England. It is hosted at the Nuffield Department of Medicine within the University of Oxford and led by the Epidemic diseases Research Group Oxford (ERGO). ISARIC is funded by the Bill & Melinda Gates Foundation, Foreign, Commonwealth and Development Office, and Wellcome Trust.

References

  1. "Personal Imperial Webpage" . Retrieved 28 December 2023.
  2. "Old Kings Club newsletter" (PDF). Retrieved 28 December 2023.
  3. Gordon, Anthony. Genetic polymorphisms of the innate immune system : influence on susceptibility and outcome in severe sepsis and septic shock. Queen Mary, University of London.
  4. "ICHT Consultant Directory" . Retrieved 28 December 2023.
  5. "UBC Faculty and Fellows" . Retrieved 28 December 2023.
  6. Annane, Djillali; Mira, Jean Paul; Ware, Lorraine B; Gordon, Anthony C; Sevransky, Jonathan; Stüber, Frank; Heagerty, Patrick J; Wellman, Hugh F; Neira, Mauricio; Mancini, Alexandra DJ; Russell, James A (December 2012). "Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)". Annals of Intensive Care. 2 (1): 15. doi: 10.1186/2110-5820-2-15 . PMC   3403963 . PMID   22694772.
  7. "Current NIHR Research Professors". www.nihr.ac.uk.
  8. Antcliffe, David B.; Burnham, Katie L.; Al-Beidh, Farah; Santhakumaran, Shalini; Brett, Stephen J.; Hinds, Charles J.; Ashby, Deborah; Knight, Julian C.; Gordon, Anthony C. (15 April 2019). "Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial". American Journal of Respiratory and Critical Care Medicine. 199 (8): 980–986. doi:10.1164/rccm.201807-1419OC. PMC   6467319 . PMID   30365341.
  9. Komorowski, Matthieu; Celi, Leo A.; Badawi, Omar; Gordon, Anthony C.; Faisal, A. Aldo (November 2018). "The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care". Nature Medicine. 24 (11): 1716–1720. doi:10.1038/s41591-018-0213-5. hdl: 10044/1/61246 . S2CID   53025350.
  10. Gordon, Anthony C.; Mason, Alexina J.; Thirunavukkarasu, Neeraja; Perkins, Gavin D.; Cecconi, Maurizio; Cepkova, Magda; Pogson, David G.; Aya, Hollmann D.; Anjum, Aisha; Frazier, Gregory J.; Santhakumaran, Shalini; Ashby, Deborah; Brett, Stephen J.; for the VANISH Investigators (2016-08-02). "Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial". JAMA. 316 (5): 509. doi:10.1001/jama.2016.10485. ISSN   0098-7484.
  11. Gordon, Anthony C.; Perkins, Gavin D.; Singer, Mervyn; McAuley, Daniel F.; Orme, Robert M.L.; Santhakumaran, Shalini; Mason, Alexina J.; Cross, Mary; Al-Beidh, Farah; Best-Lane, Janis; Brealey, David; Nutt, Christopher L.; McNamee, James J.; Reschreiter, Henrik; Breen, Andrew (2016-10-27). "Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis". New England Journal of Medicine. 375 (17): 1638–1648. doi:10.1056/NEJMoa1609409. ISSN   0028-4793.
  12. "REMAP-CAP Trial". REMAP-CAP Trial.
  13. "Arthritis drug effective in treating sickest COVID-19 patients | Imperial News | Imperial College London". Imperial News. 19 November 2020.
  14. "Prime Minister's statement on coronavirus (COVID-19): 7 January 2021". GOV.UK. 7 January 2021.
  15. REMAP-CAP Investigators; et al. (22 April 2021). "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19". New England Journal of Medicine. 384 (16): 1491–1502. doi:10.1056/NEJMoa2100433. hdl: 10044/1/86283 . PMC   7953461 . PMID   33631065. S2CID   230798728.
  16. Florescu, Simin; et al. (2023). "Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial". JAMA. 329 (1): 39–51. doi:10.1001/jama.2022.23257. PMC   9857594 . PMID   36525245.
  17. REMAP-CAP Investigators; et al. (26 August 2021). "Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19". New England Journal of Medicine. 385 (9): 777–789. doi:10.1056/NEJMoa2103417. PMC   8362592 . PMID   34351722.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  18. "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19". New England Journal of Medicine. 385 (9): 790–802. 26 August 2021. doi:10.1056/NEJMoa2105911. hdl: 10044/1/90873 . PMID   34351721. S2CID   236927358.
  19. Writing Committee for the REMAP-CAP Investigators; et al. (2023). "Effect of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized with COVID-19: A Randomized Clinical Trial". JAMA. 329 (14): 1183–1196. doi: 10.1001/jama.2023.4480 . PMC   10326520 . PMID   37039790.
  20. "Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials". JAMA. 330 (18): 1745–1759. 2023. doi: 10.1001/jama.2023.21407 . PMC  10600726. PMID   37877585.
  21. REMAP-CAP Investigators; et al. (21 December 2023). "Simvastatin in Critically Ill Patients with Covid-19". New England Journal of Medicine. 389 (25): 2341–2354. doi:10.1056/NEJMoa2309995. PMC   10755839 . PMID   37888913. S2CID   264501247.
  22. "New study will help rapidly find flu treatments this winter". www.nihr.ac.uk.
  23. "New Director for National Research Collaboration Programme announced". www.nihr.ac.uk. Retrieved 2024-03-09.
  24. "BRC researchers awarded AMS Fellowships – NIHR Imperial Biomedical Research Centre".
  25. "ICS Members meeting 2023". X.com.
  26. "NIHR appoints new Senior Investigators, including seven Imperial BRC researchers – NIHR Imperial Biomedical Research Centre" . Retrieved 28 December 2023.